Namely, KRAS, TP53, and CDKN2A, the most typical abnormalities in pancreatic cancer, were present at a low frequency, and other potentially targetable gene alterations, such as HRR genes and BRAF fusion, were more prevalent. This evidence concerns the gene KRAS and pancreatic neoplasm.